Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL Amyloidosis
Conditions
Interventions
CAEL-101
Placebo
+1 more
Locations
110
United States
Research Site
Scottsdale, Arizona, United States
Research Site
Duarte, California, United States
Research Site
Palo Alto, California, United States
Research Site
San Francisco, California, United States
Research Site
Jacksonville, Florida, United States
Research Site
Weston, Florida, United States
Start Date
November 3, 2020
Primary Completion Date
April 8, 2025
Completion Date
April 8, 2027
Last Updated
April 7, 2026
NCT06383143
NCT06192979
NCT07250269
NCT06022939
NCT04839003
NCT05066607
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions